The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a genetically defined form of advanced leukemia.
The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market.
Revuforj was approved to treat adults and children with relapsed or refractory leukemias that have a genetic “rearrangement” called KMT2A. This particular genetic type of leukemia is present in approximately 10% of cases, and is difficult to treat, leading to high relapse rates and survival of less than a year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
